Literature DB >> 21519984

Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution.

John Douglas Hoekman1, Rodney J Y Ho.   

Abstract

Many nasally applied compounds gain access to the brain and the central nervous system (CNS) with varying degree. Direct nose-to-brain access is believed to be achieved through nervous connections which travel from the CNS across the cribriform plate into the olfactory region of the nasal cavity. However, current delivery strategies are not targeted to preferentially deposit drugs to the olfactory at cribriform. Therefore, we have developed a pressurized olfactory delivery (POD) device which consistently and non-invasively deposited a majority of drug to the olfactory region of the nasal cavity in rats. Using both a hydrophobic drug, mannitol (log P = -3.1), and a hydrophobic drug, nelfinavir (log P = 6.0), and POD device, we compared brain and blood levels after nasal deposition primarily on the olfactory region with POD or nose drops which deposited primarily on the respiratory region in rats. POD administration of mannitol in rats provided a 3.6-fold (p < 0.05) increase in cortex-to-blood ratio, compared to respiratory epithelium deposition with nose drop. Administration of nelfinavir provided a 13.6-fold (p < 0.05) advantage in cortex-to-blood ratio with POD administration, compared to nose drops. These results suggest that increasing the fraction of drug deposited on the olfactory region of the nasal cavity will result in increased direct nose-to-brain transport.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519984      PMCID: PMC3134660          DOI: 10.1208/s12249-011-9614-1

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  37 in total

1.  Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage.

Authors:  X F Liu; J R Fawcett; R G Thorne; T A DeFor; W H Frey
Journal:  J Neurol Sci       Date:  2001-06-15       Impact factor: 3.181

Review 2.  Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory.

Authors:  Frans W H M Merkus; Mascha P van den Berg
Journal:  Drugs R D       Date:  2007

3.  Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein.

Authors:  Jeannie M Padowski; Gary M Pollack
Journal:  J Pharm Sci       Date:  2010-07       Impact factor: 3.534

4.  Functional evidence for P-glycoprotein at the nose-brain barrier.

Authors:  Candace L Graff; Gary M Pollack
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

5.  Histopathologic examination of the rat nasal cavity.

Authors:  J T Young
Journal:  Fundam Appl Toxicol       Date:  1981 Jul-Aug

Review 6.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats.

Authors:  H S Chow; Z Chen; G T Matsuura
Journal:  J Pharm Sci       Date:  1999-08       Impact factor: 3.534

8.  Hydroxocobalamin uptake into the cerebrospinal fluid after nasal and intravenous delivery in rats and humans.

Authors:  Mascha P Van den Berg; Paul Merkus; Stefan G Romeijn; J Coos Verhoef; Frans W H M Merkus
Journal:  J Drug Target       Date:  2003-07       Impact factor: 5.121

9.  P-Glycoprotein attenuates brain uptake of substrates after nasal instillation.

Authors:  Candace L Graff; Gary M Pollack
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

Review 10.  Nelfinavir. A review of its therapeutic efficacy in HIV infection.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1998-07       Impact factor: 9.546

View more
  11 in total

1.  Intranasal delivery of a peptide with antidepressant-like effect.

Authors:  Virginia Brown; Fang Liu
Journal:  Neuropsychopharmacology       Date:  2014-03-17       Impact factor: 7.853

2.  Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis.

Authors:  Yan-Hua Li; Jie-Zhong Yu; Chun-Yun Liu; Hui Zhang; Hai-Fei Zhang; Wan-Fang Yang; Jun-Lian Li; Qian-Jin Feng; Ling Feng; Guang-Xian Zhang; Bao-Guo Xiao; Cun-Gen Ma
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

3.  Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols.

Authors:  Xiuhua A Si; Jinxiang Xi
Journal:  J Vis Exp       Date:  2016-05-20       Impact factor: 1.355

4.  Visualization and Quantification of Nasal and Olfactory Deposition in a Sectional Adult Nasal Airway Cast.

Authors:  Jinxiang Xi; Jiayao Eddie Yuan; Yu Zhang; Dannielle Nevorski; Zhaoxuan Wang; Yue Zhou
Journal:  Pharm Res       Date:  2016-03-04       Impact factor: 4.200

5.  Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure.

Authors:  John D Hoekman; Pramod Srivastava; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2014-06-06       Impact factor: 3.534

6.  Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery.

Authors:  Niyanta N Kumar; Mohan Gautam; Jeffrey J Lochhead; Daniel J Wolak; Vamsi Ithapu; Vikas Singh; Robert G Thorne
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

Review 7.  Perivascular and Perineural Pathways Involved in Brain Delivery and Distribution of Drugs after Intranasal Administration.

Authors:  Jeffrey J Lochhead; Thomas P Davis
Journal:  Pharmaceutics       Date:  2019-11-12       Impact factor: 6.321

8.  Non-Invasive Strategies for Nose-to-Brain Drug Delivery.

Authors:  J T Trevino; R C Quispe; F Khan; V Novak
Journal:  J Clin Trials       Date:  2020-12-10

Review 9.  Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?

Authors:  Alessandro Dalpiaz; Barbara Pavan
Journal:  Pharmaceutics       Date:  2018-03-26       Impact factor: 6.321

Review 10.  Liposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives.

Authors:  Soon-Seok Hong; Kyung Taek Oh; Han-Gon Choi; Soo-Jeong Lim
Journal:  Pharmaceutics       Date:  2019-10-17       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.